Monday, June 30, 2025 6/30/2025

Genomic analysis of prostate tumor heterogeneity in metastasis

Award Number: R21CA256375
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/08/2020
PERIOD OF PERFORMANCE END DATE: 11/30/2023

Group Awards By:

View Award Description

Genomic analysis of prostate tumor heterogeneity in metastasis - Summary: Prostate cancer is a highly heterogeneous disease, and mortality from prostate cancer is due to metastases, and thus, understanding the mechanisms of metastasis is essential for improving patient outcomes. In this proposal, we plan to leverage the resources of an ongoing NIH-funded clinical trial of patients with high-risk prostate cancer who have had extensive dissection of surrounding lymph nodes and imaging with the FDA-approved radiotracer [18F]-fluciclovine, a biomarker of amino acid transport, which is upregulated in prostate cancer cells. We hypothesize that genomic analysis of multiple foci within the primary tumor, and lymph nodes positive and negative for [18F]-fluciclovine uptake and metastatic disease, will provide new insights into the mechanisms of the earliest steps in metastasis and help identify key driver mutations and signal transduction pathways. We plan to test this hypothesis via the following specific aims: Aim 1) perform whole exome sequencing of multiple primary foci and corresponding lymph nodes to identify somatic mutations associated with LN mets; Aim 2) perform RNAseq analysis of multiple primary foci and corresponding lymph nodes to identify gene expression changes associated with LN metastasis; Aim 3) determine RNA and DNA signatures associated with the presence and degree of uptake of fluciclovine in LN mets. This proposal is innovative in that we will be using multiple samples from the same patients to interrogate the heterogeneity of primary prostate tumors and the genomic and gene expression changes that drive the initial step of metastasis as they migrate to the lymph nodes. In addition, we will generate new understandings of the changes that are associated with uptake of the radiotracer [18F]-fluciclovine, which reflects upregulated amino acid metabolism in tumor cells. Discoveries from this project could lead to new approaches for treatment of advanced disease by identifying the genomic changes essential to the first steps of metastasis and defining the biology of lethal prostate cancer. New drug targets that are critical for metastasis may be identified from the knowledge gained through this study.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	000	2	4/11/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $179,252 )
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	001	2	4/26/2022	NON-COMPETING CONTINUATION	$14,635
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	000	2	1/7/2022	NON-COMPETING CONTINUATION	$164,617
														Subtotal = $179,252

Issue Date FY: 2021 ( Subtotal = $218,966 )
2021	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	000	1	12/8/2020	NEW	$218,966
														Subtotal = $218,966

Grand Total All Awards = $398,218

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Genomic analysis of prostate tumor heterogeneity in metastasis

Award Number: R21CA256375

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/08/2020

PERIOD OF PERFORMANCE END DATE: 11/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer